Selected article for: "aberrant immune response and acute respiratory syndrome"

Author: Rosen, Hugo R.; O'Connell, Casey; Nadim, Mitra K.; DeClerck, Brittney; Sheibani, Sarah; DePasquale, Eugene; Sanossian, Nerses; Blodget, Emily; Angell, Trevor
Title: Extrapulmonary Manifestations of Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Infection
  • Cord-id: bd3j4m8c
  • Document date: 2020_10_14
  • ID: bd3j4m8c
    Snippet: COVID‐19, the infectious disease caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), has resulted in a global pandemic with unprecedented health, societal and economic impact. The disease often manifests with flu‐like symptoms and is dominated by pulmonary complications, but widely diverse clinical manifestations involving multiple organ systems can result. We posit that viral tropism and the aberrant host immune response mediate the protean findings and severity in
    Document: COVID‐19, the infectious disease caused by severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), has resulted in a global pandemic with unprecedented health, societal and economic impact. The disease often manifests with flu‐like symptoms and is dominated by pulmonary complications, but widely diverse clinical manifestations involving multiple organ systems can result. We posit that viral tropism and the aberrant host immune response mediate the protean findings and severity in this disease. In general, extrapulmonary manifestations are a harbinger of or contemporaneously associate with disease progression, but in the case of some extrapulmonary findings (GI and dermatologic), may track with milder disease. The precise underlying pathophysiological mechanisms remain incompletely elucidated, and additional immune phenotyping studies are warranted to reveal early correlates of disease outcomes and novel therapeutic targets. This article is protected by copyright. All rights reserved.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute aki kidney injury: 1, 2, 3, 4, 5, 6
    • abdominal pain and acute tubular injury: 1, 2
    • abdominal pain and ade antibody dependent enhancement: 1
    • abdominal pain and live virus: 1
    • abdominal pain and lopinavir ritonavir: 1, 2, 3, 4
    • abdominal pain and low lymphocyte count: 1, 2
    • abdominal pain and low molecular: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • abdominal pain and low molecular heparin prophylaxis: 1
    • abdominal pain and lung inflammation: 1
    • abdominal pain and lung tissue: 1, 2
    • abdominal pain and lymph node: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and lymphocyte count: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abnormal liver and acute aki kidney injury: 1, 2, 3
    • abnormal liver and liver biochemistry: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • abnormal liver and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • abnormal liver and lopinavir ritonavir treatment: 1, 2, 3, 4
    • abnormal liver and low lymphocyte count: 1
    • abnormal liver and low molecular: 1
    • abnormal liver and lung inflammation: 1, 2